• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巴西的再生医学:虽小但具创新性。

Regenerative medicine in Brazil: small but innovative.

机构信息

McLaughlin-Rotman Centre for Global Health, University Health Network and University of Toronto, Toronto, ON, M5G 1L7, Canada.

出版信息

Regen Med. 2010 Nov;5(6):863-76. doi: 10.2217/rme.10.76.

DOI:10.2217/rme.10.76
PMID:21082887
Abstract

AIMS

Although Brazil has received attention for conducting one of the world's largest stem cell clinical trials for heart disease, little has been published regarding Brazil's regenerative medicine (RM) sector. Here we present a comprehensive case study of RM in Brazil, including analysis of the current activity, the main motivations for engaging in RM and the remaining challenges to development in this field.

METHODS

Our case study is primarily based on semi-structured interviews with experts on RM in Brazil, including researchers, policymakers, clinicians, representatives of firms and regulators.

RESULTS

Driven by domestic health needs and strategic government support, Brazil is producing innovative RM research, particularly for clinical research in cardiology, orthopedics, diabetes and neurology. We describe the main RM research currently taking place in Brazil, as well as some of the economic, regulatory and policy events that have created a favorable environment for RM development. Brazilian RM researchers need to overcome several formidable challenges to research: research funding is inconsistent, importation of materials is costly and slow, and weak linkages between universities, hospitals and industry impede translational research.

CONCLUSIONS

Although Brazil's contribution to the RM sector is small, its niche emphasis on clinical applications may become of global importance, particularly if Brazil manages to address the challenges currently impinging on RM innovation.

摘要

目的

尽管巴西因开展世界上最大的心脏病干细胞临床试验之一而受到关注,但关于巴西再生医学(RM)领域的信息却很少。本文对巴西的 RM 进行了全面的案例研究,包括对当前活动的分析、从事 RM 的主要动机以及该领域发展面临的剩余挑战。

方法

我们的案例研究主要基于对巴西 RM 专家的半结构化访谈,包括研究人员、政策制定者、临床医生、公司和监管机构的代表。

结果

受国内卫生需求和政府战略支持的推动,巴西正在开展创新性的 RM 研究,特别是在心脏病学、骨科、糖尿病和神经病学的临床研究方面。我们描述了巴西目前正在进行的主要 RM 研究,以及一些为 RM 发展创造有利环境的经济、监管和政策事件。巴西 RM 研究人员需要克服研究方面的几个严峻挑战:研究资金不稳定,材料的进口既昂贵又缓慢,大学、医院和工业之间的联系薄弱,阻碍了转化研究。

结论

尽管巴西对 RM 部门的贡献很小,但它在临床应用方面的特色重点可能会变得具有全球重要性,特别是如果巴西能够解决当前影响 RM 创新的挑战。

相似文献

1
Regenerative medicine in Brazil: small but innovative.巴西的再生医学:虽小但具创新性。
Regen Med. 2010 Nov;5(6):863-76. doi: 10.2217/rme.10.76.
2
Cultivating regenerative medicine innovation in China.培育中国的再生医学创新。
Regen Med. 2010 Jan;5(1):35-44. doi: 10.2217/rme.09.78.
3
Evolution of Business Models in Regenerative Medicine: Effects of a Disruptive Innovation on the Innovation Ecosystem.再生医学商业模式的演变:颠覆性创新对创新生态系统的影响。
Clin Ther. 2018 Jul;40(7):1084-1094. doi: 10.1016/j.clinthera.2018.06.003. Epub 2018 Jul 23.
4
Ethical implications of regenerative medicine in orthopedics: an empirical study with surgeons and scientists in the field.骨科再生医学的伦理影响:一项针对该领域外科医生和科学家的实证研究
Spine J. 2014 Jun 1;14(6):1029-35. doi: 10.1016/j.spinee.2013.10.016. Epub 2013 Nov 1.
5
Regenerative medicine, resource and regulation: lessons learned from the remedi project.再生医学、资源与监管:从 REMEDI 项目中吸取的教训。
Regen Med. 2011 Mar;6(2):241-53. doi: 10.2217/rme.10.89.
6
Promoting justice in stem cell intellectual property.促进干细胞知识产权中的公正。
Regen Med. 2011 Nov;6(6 Suppl):79-84. doi: 10.2217/rme.11.68.
7
Stem-cell agency faces budget dilemma.干细胞机构面临预算困境。
Nature. 2012 Jan 31;482(7383):15. doi: 10.1038/482015a.
8
Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.英国再生医学产品商业化障碍的行业认知。
Regen Med. 2009 Jul;4(4):549-59. doi: 10.2217/rme.09.21.
9
Global update: Germany.全球更新:德国。
Regen Med. 2011 Nov;6(6 Suppl):154-7. doi: 10.2217/rme.11.64.
10
Exploring innovation in stem cell and regenerative medicine in Japan: the power of the consortium-based approach.探索日本干细胞与再生医学领域的创新:基于联盟模式的力量。
Regen Med. 2014;9(4):467-77. doi: 10.2217/rme.14.18.

引用本文的文献

1
Clinical use of autologous cell-based therapies in an evolving regulatory landscape: A survey of patient experiences and perceptions.在不断发展的监管环境下,自体细胞疗法的临床应用:一项关于患者体验和看法的调查。
F1000Res. 2024 Aug 27;12:1165. doi: 10.12688/f1000research.141002.2. eCollection 2023.
2
A practical approach for adoption of a hub and spoke model for cell and gene therapies in low- and middle-income countries: framework and case studies.一种在中低收入国家采用细胞和基因治疗中心辐射式模式的实用方法:框架与案例研究。
Gene Ther. 2024 Jan;31(1-2):1-11. doi: 10.1038/s41434-023-00425-x. Epub 2023 Oct 30.
3
Cell therapy in Brazil: time for reflection.
巴西的细胞疗法:反思时刻。
Rev Bras Hematol Hemoter. 2013;35(5):296-8. doi: 10.5581/1516-8484.20130117.
4
Sino-Canadian collaborations in stem cell research: a scientometric analysis.中加干细胞研究合作:一项科学计量分析。
PLoS One. 2013;8(2):e57176. doi: 10.1371/journal.pone.0057176. Epub 2013 Feb 28.
5
In Brazil, basic stem cell research lags behind clinical trials.
Nat Med. 2011 Oct 11;17(10):1172. doi: 10.1038/nm1011-1172.
6
Fulfillment of the brazilian agenda of priorities in health research.实现巴西卫生研究重点议程。
Health Res Policy Syst. 2011 Aug 31;9:35. doi: 10.1186/1478-4505-9-35.